CRS

ISS National Lab-Sponsored Research Could Produce Nanomaterials for Life-Saving Therapies and Precision Drug Delivery

Retrieved on: 
Giovedì, Aprile 25, 2024
Janus, SpaceX, SPACE, University, Cancer, ISS, Biomedical engineering, International Space Station, CRS, NASA, United States national laboratories, JBN, Commercial Resupply Services, Research, Nanoparticle, Engineering, Arthritis, Joint, Therapy, Science, Axiom Mission 2, DSM-IV codes, Messenger, Cartilage, Axiom Space, Temperature, Pharmaceutical industry

However, all this might soon change, thanks to a new investigation led by biomedical engineering researchers at the University of Connecticut.

Key Points: 
  • However, all this might soon change, thanks to a new investigation led by biomedical engineering researchers at the University of Connecticut.
  • Besides arthritis, these potentially life-saving nanomaterials could also treat cancer and neurological disorders.
  • Yupeng Chen, an associate professor for biomedical engineering at the university, is partnering with Eascra Biotech and Axiom Space to leverage the unique conditions available through the International Space Station (ISS) National Laboratory to produce DNA-inspired Janus base nanomaterials (JBNs).
  • The project, which was funded by the U.S. National Science Foundation, is still ongoing, but Chen says initial results from the research are very promising.

Mandalay Extends the Storheden Gold Deposit Adjacent to the Operating Björkdal Mine

Retrieved on: 
Mercoledì, Aprile 24, 2024
CRS, MAIG, Appendix, Laboratory, Technical report, TSX, QA/QC, Metallurgy, Gold, Instrument, Season, ETW, Geo, Vein, Mining

This press release is the first in a series of updates on our 2024 regional exploration progress at Björkdal.

Key Points: 
  • This press release is the first in a series of updates on our 2024 regional exploration progress at Björkdal.
  • This deposit has not been thoroughly explored in comparison to our extensive Björkdal deposit however it is showing promising signs of gold mineralization.
  • The Storheden deposit is located roughly 600 m to the Northeast of the Björkdal mine (Figure 2-3).
  • Despite its promising structural setting, the 2023 drilling showed that this area lacks the pervasive veining characterizing the Björkdal and Storheden deposits.

Mandalay Extends the Storheden Gold Deposit Adjacent to the Operating Björkdal Mine

Retrieved on: 
Mercoledì, Aprile 24, 2024
CRS, MAIG, Appendix, Laboratory, Technical report, TSX, QA/QC, Metallurgy, Gold, Instrument, Season, ETW, Geo, Vein, The Company, Mining

This press release is the first in a series of updates on our 2024 regional exploration progress at Björkdal.

Key Points: 
  • This press release is the first in a series of updates on our 2024 regional exploration progress at Björkdal.
  • This deposit has not been thoroughly explored in comparison to our extensive Björkdal deposit however it is showing promising signs of gold mineralization.
  • The Storheden deposit is located roughly 600 m to the Northeast of the Björkdal mine (Figure 2-3).
  • Despite its promising structural setting, the 2023 drilling showed that this area lacks the pervasive veining characterizing the Björkdal and Storheden deposits.

EQS-News: CRS appoints Catherine Canales as new Chief Commercial Officer to fuel strategic development and international growth

Retrieved on: 
Mercoledì, Aprile 10, 2024
Research, Culture, Growth, Business, Patient, CRS, Contract research organization, CCO, Marketing, Management

Mannheim, Germany, April 10, 2024 – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Catherine Canales as Chief Commercial Officer (CCO), effective today, completing the new CRS leadership team.

Key Points: 
  • Mannheim, Germany, April 10, 2024 – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Catherine Canales as Chief Commercial Officer (CCO), effective today, completing the new CRS leadership team.
  • Together, they are committed to steering the company's strategic development, growth, and innovation on a global scale.
  • Dr. Elisabeth Lackner, CEO of CRS, commented on the appointment: “It is a great pleasure to welcome Catherine on board the CRS management team.
  • Before that, she served as Director, Business Development at Premier Research, driving business growth and sales by promoting phase I-IV clinical development services.

EQS-News: CRS initiates new chapter by appointing leading industry expert Elisabeth Lackner as Chief Executive Officer

Retrieved on: 
Mercoledì, Aprile 10, 2024
University, Growth, Vineta, Patient, Knowledge, Element, CRS, Doctor of Philosophy, Contract research organization, QP, Investment, Qualified person (European Union), CSO, Management

Mannheim, Germany, March 15, 2024 – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Dr. Elisabeth Lackner as Chief Executive Officer (CEO), effective today.

Key Points: 
  • Mannheim, Germany, March 15, 2024 – CRS Clinical Research Services, an expert early-phase Contract Research Organization (CRO), today announced the appointment of Dr. Elisabeth Lackner as Chief Executive Officer (CEO), effective today.
  • Dr. Elisabeth Lackner, CEO of CRS, commented: “I am honoured to join this great management team and to guide the organization into its next chapter of strategic growth and innovation.
  • “Together, we aim to propel CRS to new heights, centred on internationalization, strategic expansion, and a relentless pursuit of excellence."
  • Dr. Lackner is a highly experienced and well-respected global thought leader with over 20 years of experience in the healthcare industry.

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024

Retrieved on: 
Lunedì, Aprile 8, 2024
Failure, Toxicity, Disease, Patient, Nebraska Medicine, University, Cancer research, PRS, Freezing, AACR, Neoplasm, Metastasis, Immune system, ASCO, Medical research, CRS, Pharmaceutical industry

FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024. The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.        

Key Points: 
  • FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.
  • The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had experienced failure with prior therapies.
  • The trial is ongoing, with results expected in the second half of 2024.

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Retrieved on: 
Lunedì, Aprile 8, 2024
Principal, Malignancy, Risk, Patient, Food and Drug Administration, City, CRS, NHL, Mutagenesis, Therapy, Hematology, Bone marrow, B-cell lymphoma, APOLLO, Neurotoxicity, DLBCL, Cytokine release syndrome, Lymphoma, Press release

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

Key Points: 
  • Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
  • During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601.
  • This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
  • Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope.

Carpenter Technology Announces Conference Call and Webcast

Retrieved on: 
Venerdì, Aprile 5, 2024
Webcast, Carpenter Technology Corporation, CRS

PHILADELPHIA , April 05, 2024 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Wednesday, May 1, 2024 at 10:00 a.m.

Key Points: 
  • PHILADELPHIA , April 05, 2024 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Wednesday, May 1, 2024 at 10:00 a.m.
  • ET to discuss the results of operations for the third quarter of fiscal year 2024, ended March 31, 2024.
  • The call and webcast will follow the release of third quarter fiscal 2024 financial results before the market opens on Wednesday, May 1, 2024.

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Retrieved on: 
Giovedì, Aprile 4, 2024
Risk, Sensei, Patient, Research, Tumor microenvironment, Manuscript, CRS, Cancer, Trial of the century, Cytokine release syndrome, Myelocyte, Antibody, Safety, Therapy, VISTA, Nature Communications, PD-1, Vaccine

The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Key Points: 
  • The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
  • The paper describes Sensei Biotherapeutics’ approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation.
  • SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation.
  • The manuscript published in Nature Communications is entitled “VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response,” and can be found here: https://rdcu.be/dDF8x

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Retrieved on: 
Giovedì, Aprile 4, 2024
B-cell lymphoma, Toxicity, Associate, Part, Patient, CRS, University, Doctor of Philosophy, Therapy, Diffuse large B-cell lymphoma, Infrared spectroscopy correlation table, Division, ADC, Hematology, Cytokine release syndrome, Lymphoma, Follicular lymphoma, Pharmaceutical industry

LAUSANNE, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Key Points: 
  • Additionally, after the first investigator assessment, evidence of anti-tumor activity was observed among the majority of patients, with mixed histologies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL).
  • “The early data from Part 1 of our LOTIS-7 trial highlight the potential combinability of ZYNLONTA with bispecifics in lymphoma patients,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs).
  • For more information about the LOTIS-7 trial, visit clinicaltrials.gov (NCT04970901).